01 September 2022
Launch of new corporate brand and website
Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), announces the launch of its new corporate brand and website.
The new corporate brand and website aligns with the Company's future vision and presents the significant transformation the Group has undergone, following new leadership and the successful launch of Accrufer® in the US. The new brand identity embodies the renewed sense of purpose, energy and enthusiasm of all its employees with a bright, progressive and dynamic feel representing a company that has transformed itself and is on a growth trajectory. Additionally, the new website provides key stakeholders, partners, and investors with a more modern and cleaner look and feel, making it easier to navigate and locate all up to date information and resources.
Greg Madison, Chief Executive Officer of Shield Therapeutics, said: "The launch of our new corporate brand and website is timely as we continue to make excellent progress by the 'new' Shield ethos and are pleased to offer our key stakeholders an updated website in order to learn more about our business, strategy and geographical markets that we are operating in. This is another step forward to help achieve our mission 'to improve lives together' and make Accrufer® the treatment of choice to treat iron deficiency."